U.S. biologics and biosimilars need distinguishable names - STAT

U.S. biologics and biosimilars need distinguishable names - STAT

U.S. biologics and biosimilars need distinguishable names

By BRAD JORDAN

ADOBE

The FDA's plan to give biologics and biosimilars distinguishable nonproprietary names is a well-informed approach that puts patient care first.

READ MORE